EVO756

May 7, 2026: Evommune, Inc. (NYSE: EVMN) reported 1Q26 financial results and outlined upcoming clinical and conference catalysts for its inflammation pipeline.

EVO756 (oral MRGPRX2 antagonist):

• CSU: Enrollment complete in a Phase 2b dose-ranging trial (N=160) in moderate-to-severe chronic spontaneous urticaria; top-line data expected June 2026.
• Atopic dermatitis (AD): Enrollment complete in a Phase 2b dose-ranging trial (N=120) in moderate-to-severe AD; top-line data expected in 3Q 2026.
• Migraine prophylaxis: Plans to initiate a Phase 2b dose-ranging trial in mid-2026; top-line data anticipated in 2027.
• Upcoming presentations: Posters at AHS Annual Scientific Meeting (June 4–7, 2026) and FOCIS Annual Meeting (June 9–12, 2026) with translational data related to MRGPRX2 in urticaria, AD, and migraine.

EVO301 (injectable IL-18 binding protein fusion protein):

• Following positive Phase 2a proof-of-concept data in AD (reported February 2026), the company completed a high-concentration subcutaneous formulation and initiated manufacturing.
• Phase 2b AD trial (placebo-controlled, dose-ranging; ≥3 regimens; 16-week treatment) planned to start mid-2027 after scale-up and toxicology.
• Preclinical data to be presented at SID Annual Meeting (May 13–16, 2026).

Financials: Cash/cash equivalents/investments were $307.0M as of March 31, 2026; 1Q26 net loss was $21.7M. The company states cash is expected to fund operations through 2028.